| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Circulation, Vol 90, 2457-2467, Copyright © 1994 by American Heart Association
KC Wollert, R Studer, B von Bulow and H Drexler
BACKGROUND--Chronic treatment with high doses of angiotensin-converting
enzyme (ACE) inhibitors prolongs survival after myocardial infarction.
Since the plasma renin-angiotensin system (RAS) is not consistently
activated in the chronic phase after myocardial infarction, the beneficial
effects of ACE inhibition have been attributed, in part, to inhibition of
an activated tissue RAS. However, a relation between tissue ACE inhibition
and long-term efficacy (ie, concerning left ventricular [LV] hypertrophy
and survival) has not been established. The present study was designed to
evaluate the impact of low-dose ACE inhibition (predominant inhibition of
plasma ACE) and high-dose ACE inhibition associated with substantial tissue
ACE inhibition) on reversal of LV hypertrophy and 1-year mortality after
myocardial infarction in the rat. METHODS AND RESULTS--Infarcted rats were
randomized to placebo, low-dose lisinopril, or high-dose lisinopril (each,
n = 80) and compared with sham-operated animals (n = 40). In a separate
group of animals, tissue ACE activity was determined after 6 weeks of
therapy, demonstrating that both regimens were effective with regard to
both plasma and pulmonary ACE inhibition; however, only high- dose
lisinopril inhibited renal ACE. Neither dose affected LV ACE activity and
ACE mRNA levels as determined by competitive polymerase chain reaction,
whereas LV ANF mRNA levels were significantly reduced by high-dose
lisinopril. High-dose lisinopril reduced arterial blood pressure and
normalized right ventricular and LV weight and resulted in a substantial
reduction of 1-year mortality, whereas the low dose did not (1 year
mortality: placebo, 56.3%; low dose, 53.3%; high dose, 22.9%, P < .0001
versus low dose and versus placebo). CONCLUSIONS-- Hemodynamically
effective ACE inhibition is required for reduction of LV hypertrophy and
long-term mortality after myocardial infarction in the rat. Sustained
inhibition of renal ACE during long-term therapy may contribute to the
beneficial effect of high-dose lisinopril. Low-dose lisinopril, although
exerting sustained inhibition of the plasma ACE, does not improve survival
after myocardial infarction.
ARTICLES
Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition
Medizinische Klinik III, Universitat Freiburg, Germany.
This article has been cited by other articles:
 |
|
 |
|
  X. Xu, W. Wan, L. Ji, S. Lao, A. S. Powers, W. Zhao, J. M. Erikson, and J. Q. Zhang Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats Cardiovasc Res, June 1, 2008; 78(3): 523 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-J. Zou, L. Yang, and S.-L. Yao Propofol Depresses Angiotensin II-Induced Cardiomyocyte Hypertrophy In Vitro Experimental Biology and Medicine, February 1, 2008; 233(2): 200 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 31 - 45. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Westendorp, R. G. Schoemaker, H. Buikema, F. Boomsma, D. J. van Veldhuisen, and W. H. van Gilst Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction Eur J Heart Fail, March 1, 2006; 8(2): 122 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Westendorp, R. G. Schoemaker, H. Buikema, D. de Zeeuw, F. Boomsma, W. H. van Gilst, and D. J. van Veldhuisen Beneficial effects of add-on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril Eur J Heart Fail, December 1, 2005; 7(7): 1085 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Cowling, X. Zhang, V. C. Reese, M. Iwata, D. Gurantz, W. H. Dillmann, and B. H. Greenberg Effects of cytokine treatment on angiotensin II type 1A receptor transcription and splicing in rat cardiac fibroblasts Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1176 - H1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mellin, M. Isabelle, A. Oudot, C. Vergely-Vandriesse, C. Monteil, B. Di Meglio, J. P. Henry, B. Dautreaux, L. Rochette, C. Thuillez, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure Eur. Heart J., August 1, 2005; 26(15): 1544 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tongers, B. Fiedler, D. Konig, T. Kempf, G. Klein, J. Heineke, T. Kraft, S. Gambaryan, S. M Lohmann, H. Drexler, et al. Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes Cardiovasc Res, August 15, 2004; 63(3): 545 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Westendorp, R. G Schoemaker, H. Buikema, D. de Zeeuw, D. J van Veldhuisen, and W. H van Gilst Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 27 - 32. [Abstract] [PDF]
|
|
|
|
|
|
A. Schafer, D. Fraccarollo, P. Tas, I. Schmidt, G. Ertl, and J. Bauersachs Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism Eur J Heart Fail, March 1, 2004; 6(2): 151 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jin, S. Takai, M. Yamada, M. Sakaguchi, K. Kamoshita, K. Ishida, Y. Sukenaga, and M. Miyazaki Impact of chymase inhibitor on cardiac function and survival after myocardial infarction Cardiovasc Res, November 1, 2003; 60(2): 413 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Linz, G. Itter, L. W Dobrucki, T. Malinski, and G. Wiemer Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 180 - 185. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Cittadini, J.o. Isgaard, M. G. Monti, C. Casaburi, A. Di Gianni, R. Serpico, G. Iaccarino, and L. Sacca Growth hormone prolongs survival in experimental postinfarction heart failure J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2154 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Maki, Y. Nasa, K. Tanonaka, M. Takahashi, and S. Takeo Beneficial Effects of Sampatrilat, a Novel Vasopeptidase Inhibitor, on Cardiac Remodeling and Function of Rats with Chronic Heart Failure following Left Coronary Artery Ligation J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 97 - 105. [Abstract] [Full Text]
|
|
|
|
|
|
M. Nahrendorf, K. Hu, D. Fraccarollo, K.-H. Hiller, A. Haase, W. R. Bauer, and G. Ertl Time course of right ventricular remodeling in rats with experimental myocardial infarction Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H241 - H248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nahrendorf, K. Hu, K.-H. Hiller, P. Galuppo, D. Fraccarollo, G. Schweizer, A. Haase, G. Ertl, W. R. Bauer, and J. Bauersachs Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: An experimental serial cardiac magnetic resonance imaging study J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1695 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nomoto, T. Nishina, S. Miwa, H. Tsuneyoshi, I. Maruyama, K. Nishimura, and M. Komeda Angiotensin-Converting Enzyme Inhibitor Helps Prevent Late Remodeling After Left Ventricular Aneurysm Repair in Rats Circulation, September 24, 2002; 106(12_suppl_1): I-115 - I-119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, H. Boujedaini, V. Richard, J.-P. Henry, S. Renet, K. Munter, and C. Thuillez Long-Term Survival and Hemodynamics After Endothelin-A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition in Rats With Chronic Heart Failure: Monotherapy Versus Combination Therapy Circulation, August 27, 2002; 106(9): 1159 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Wisloff, J. P. Loennechen, S. Currie, G. L. Smith, and O. Ellingsen Aerobic exercise reduces cardiomyocyte hypertrophy and increases contractility, Ca2+ sensitivity and SERCA-2 in rat after myocardial infarction Cardiovasc Res, April 1, 2002; 54(1): 162 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Cowling, D. Gurantz, J. Peng, W. H. Dillmann, and B. H. Greenberg Transcription Factor NF-kappa B Is Necessary for Up-regulation of Type 1 Angiotensin II Receptor mRNA in Rat Cardiac Fibroblasts Treated with Tumor Necrosis Factor-alpha or Interleukin-1beta J. Biol. Chem., February 15, 2002; 277(8): 5719 - 5724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bauersachs, M. Heck, D. Fraccarollo, S. K. Hildemann, G. Ertl, M. Wehling, and M. Christ Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression J. Am. Coll. Cardiol., January 16, 2002; 39(2): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wiemer, G. Itter, T. Malinski, and W. Linz Decreased Nitric Oxide Availability in Normotensive and Hypertensive Rats With Failing Hearts After Myocardial Infarction Hypertension, December 1, 2001; 38(6): 1367 - 1371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Palojoki, A. Saraste, A. Eriksson, K. Pulkki, M. Kallajoki, L.-M. Voipio-Pulkki, and I. Tikkanen Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2726 - H2731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Cohen, X.-M. Yang, T. Neumann, G. Heusch, and J. M. Downey Favorable Remodeling Enhances Recovery of Regional Myocardial Function in the Weeks After Infarction in Ischemically Preconditioned Hearts Circulation, August 1, 2000; 102(5): 579 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hanon, P. Vijayaraman, E. H Sonnenblick, and T. H Le Jemtel Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 147 - 150. [PDF]
|
|
|
|
|
|
U. P. Jorde, P. V. Ennezat, J. Lisker, V. Suryadevara, J. Infeld, S. Cukon, A. Hammer, E. H. Sonnenblick, and T. H. Le Jemtel Maximally Recommended Doses of Angiotensin-Converting Enzyme (ACE) Inhibitors Do Not Completely Prevent ACE-Mediated Formation of Angiotensin II in Chronic Heart Failure Circulation, February 29, 2000; 101(8): 844 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Packer, P. A. Poole-Wilson, P. W. Armstrong, J. G. F. Cleland, J. D. Horowitz, B. M. Massie, L. Ryden, K. Thygesen, and B. F. Uretsky Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure Circulation, December 7, 1999; 100(23): 2312 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C Wollert and H. Drexler The renin-angiotensin system and experimental heart failure Cardiovasc Res, September 1, 1999; 43(4): 838 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gurantz, R. T. Cowling, F. J. Villarreal, and B. H. Greenberg Tumor Necrosis Factor-{alpha} Upregulates Angiotensin II Type 1 Receptors on Cardiac Fibroblasts Circ. Res., August 6, 1999; 85(3): 272 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bauersachs, A. Bouloumie, D. Fraccarollo, K. Hu, R. Busse, and G. Ertl Endothelial Dysfunction in Chronic Myocardial Infarction Despite Increased Vascular Endothelial Nitric Oxide Synthase and Soluble Guanylate Cyclase Expression : Role of Enhanced Vascular Superoxide Production Circulation, July 20, 1999; 100(3): 292 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Silvestre, C. Heymes, A. Oubenaissa, V. Robert, B. Aupetit-Faisant, A. Carayon, B. Swynghedauw, and C. Delcayre Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction : Effect of Angiotensin II Receptor Blockade and Role in Cardiac Fibrosis Circulation, May 25, 1999; 99(20): 2694 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Marie, C. Mossiat, C. Gros, J.-C. Schwartz, J.-M. Lecomte, and J. Bralet Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction Cardiovasc Res, March 1, 1999; 41(3): 544 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Richer, P. Fornes, C. Cazaubon, V. Domergue, D. Nisato, and J.-F. Giudicelli Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats Cardiovasc Res, January 1, 1999; 41(1): 100 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ren, A. Lukas, Q. Shao, M. Guo, N. Takeda, R. M. Aitken, and N. S. Dhalla Electrocardiographic Changes and Mortality Due to Myocardial Infarction in Rats With or Without Imidapril Treatment Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(1): 11 - 21. [Abstract] [PDF]
|
|
|
|
|
|
J. Wharton, K. Morgan, R. A. D. Rutherford, J. D. Catravas, A. Chester, B. F. Whitehead, M. R. D. Leval, M. H. Yacoub, and J. M. Polak Differential Distribution of Angiotensin AT2 Receptors in the Normal and Failing Human Heart J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 323 - 336. [Abstract] [Full Text]
|
|
|
|
|
|
K. T. Weber Extracellular Matrix Remodeling in Heart Failure : A Role for De Novo Angiotensin II Generation Circulation, December 2, 1997; 96(11): 4065 - 4082. [Full Text]
|
|
|
|
|
|
J. Menard, D. J. Campbell, M. Azizi, and M.-F. Gonzales Synergistic Effects of ACE Inhibition and Ang II Antagonism on Blood Pressure, Cardiac Weight, and Renin in Spontaneously Hypertensive Rats Circulation, November 4, 1997; 96(9): 3072 - 3078. [Abstract] [Full Text]
|
|
|
|
|
|
K. C. Wollert, R. Studer, K. Doerfer, E. Schieffer, C. Holubarsch, H. Just, and H. Drexler Differential Effects of Kinins on Cardiomyocyte Hypertrophy and Interstitial Collagen Matrix in the Surviving Myocardium After Myocardial Infarction in the Rat Circulation, April 1, 1997; 95(7): 1910 - 1917. [Abstract] [Full Text]
|
|
|
|
|
|
P. Mulder, B. Devaux, V. Richard, J.-P. Henry, M.-C. Wimart, E. Thibout, B. Mace, and C. Thuillez Early Versus Delayed Angiotensin-Converting Enzyme Inhibition in Experimental Chronic Heart Failure: Effects on Survival, Hemodynamics, and Cardiovascular Remodeling Circulation, March 4, 1997; 95(5): 1314 - 1319. [Abstract] [Full Text]
|
|
|
|
|
|
T. Ogawa, W. Linz, M. Stevenson, B. G. Bruneau, M. L. Kuroski de Bold, J. H. Chen, H. Eid, B. A. Scholkens, and A. J. de Bold Evidence for Load-Dependent and Load-Independent Determinants of Cardiac Natriuretic Peptide Production Circulation, June 1, 1996; 93(11): 2059 - 2067. [Abstract] [Full Text]
|
|
|
|
|
|
N. K. Hollenberg and N. D. L. Fisher Renal Circulation and Blockade of the Renin-Angiotensin System : Is Angiotensin-Converting Enzyme Inhibition the Last Word? Hypertension, October 1, 1995; 26(4): 602 - 609. [Abstract] [Full Text]
|
|